United Therapeutics (UTHR) announced the first clinical xenotransplantation in its EXPAND study of the UKidney in patients with end-stage renal disease. The successful transplant operation was performed at NYU Langone Health.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $587 from $569 at RBC Capital
- United Therapeutics price target raised to $525 from $500 at H.C. Wainwright
- United Therapeutics price target raised to $447 from $435 at Morgan Stanley
- United Therapeutics: Hold Rating Amid Optimistic Partnership Prospects and Adjusted Revenue Goals
- United Therapeutics Reports Record Q3 2025 Results